Wells Fargo analyst Brandon Couillard raised the firm’s price target on Natera (NTRA) to $220 from $215 and keeps an Equal Weight rating on the shares. The firm notes Q1 revenue beat consensus, even excluding a $50M true-up, on record quarter-over-quarter growth in Signatera & Women’s Health volumes. FY26 revenue guide moved up $120M but still leaves room for upside, while R&D spend is ticking up on trial timing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera: Strong Q1 Beat, Raised Guidance Support Buy Rating with Unchanged $280 Price Target
- Natera reports Q1 EPS -60c, consensus -55c
- Natera sees 2026 revenue $2.74B-$2.82B, consensus $2.67B
- Natera announces evidence for Prospera test at 2026 ISHLT
- Spotify, Sandisk, Natera, Biogen, Tesla Trending With Analysts